Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Cardiac failure aggravated; This is a spontaneous report from a contactable physician downloaded from the Regulatory Authority FR-AFSSAPS-DJ20210391 (Regulatory Authority reference) An 89-year-old male patient received the first dose of bnt162b2 (COMIRNATY), Lot PAA156571, intramuscular at single dose in the left arm, on 29Jan2021 for COVID-19 immunisation. Medical history included cardiac failure chronic for several months. Concomitant medications were not reported. On 30Jan2021, the patient experienced cardiac failure aggravated with fata outcome. The patient died on 30Jan2021. An autopsy was not performed. The death was expected for several weeks. This patient was considered to be at risk of developing a severe form of the COVID-19 disease. The patient had not had COVID-19 and had not been tested. After contact with her physician: patient in palliative care for several months. Did not present an immediate post-vaccination problem. Did not have a fever. Had not benefited from any particular monitoring of blood pressure or heart rate given his general condition, which was already very impaired. Reporting taking into account the chronology with a death the day after vaccination. The specific role of the vaccine not clearly retained. No follow-up attempts are possible. No further information is expected.; Reported Cause(s) of Death: End stage cardiac failure
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166